Evaluation of implementation of evolving practice patterns in the first-line treatment of patients with metastatic non-small cell lung cancer in Turkiye (ESTIMATE): a national, multicenter, retrospective, real-world evidence study
Makaleler > Tam Makale · 2025
Yazarlar: Mehmet Ali Nahit Sendur, Nuri Karadurmus, Irfan Cicin, Mahmut Gumus, Umut Demirci, Ozgur Ozyilkan, Muhammet Ali Kaplan, Sema Sezgin Goksu, Feyyaz Ozdemir, Cagatay Arslan, Basak Oyan Uluc, Erdem GÖKER, Muhammed Mustafa Oksuzokyar, Yasemin Esen, Mert Batum, Milan van Rheenan, Bernadette Poellinger
Future Oncology, Uluslararası, Wos, 2025, cilt 21, ss 2525-2535
DOI: 10.1080/14796694.2025.2527477
Özet
BACKGROUND: This national, multicenter, retrospective, non-interventional real-world evidence study aimed to address patient characteristics and systemic treatment practices of metastatic non-small cell lung cancer (mNSCLC) patients in Türkiye. RESEARCH DESIGN AND METHODS: Over 6 months, 636 adults with mNSCLC at 12 Turkish oncology centers provided retrospective data. RESULTS: Adenocarcinoma was the most common histology, with 95% having distant bone metastases and 64.8% having no comorbidities. The most frequently administered first-line therapy was combination chemotherapy followed by targeted therapy and immunotherapy. Overall, 55.5-69.3% of patients were tested for ALK, EGFR, ROS1, and PD-L1. CONCLUSIONS: Biomarker screening in mNSCLC patients in Türkiye was suboptimal compared to other countries, especially in public hospitals.